New therapeutics for chronic heart failure

Douglas L. Mann; Anita Deswal; Biykem Bozkurt; Guillermo Torre-Amione

doi:10.1146/annurev.med.53.082901.104004

New therapeutics for chronic heart failure

Douglas L. Mann, Anita Deswal, Biykem Bozkurt, Guillermo Torre-Amione

Research output: Contribution to journal › Review article › peer-review

59 Scopus citations

Abstract

Traditionally, clinicians have viewed heart failure either as a problem of excessive salt and water retention caused by abnormalities of renal blood flow, or as a hemodynamic problem associated with a reduced cardiac output and excessive peripheral vasoconstriction. Recently, clinicians have begun to adopt a neurohormonal model in which heart failure progresses because of the toxic effects of endogenous biological systems that become activated in heart failure. We review the rationale for existing heart failure therapies and discuss the reasoning behind the development of some emerging therapies.

Original language	English (US)
Pages (from-to)	59-74
Number of pages	16
Journal	Annual Review of Medicine
Volume	53
DOIs	https://doi.org/10.1146/annurev.med.53.082901.104004
State	Published - 2002
Externally published	Yes

Keywords

Adrenergic nervous system
Cyokines
Left ventricular remodeling
Renin angiotensin system

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1146/annurev.med.53.082901.104004

Cite this

@article{194d348c4b224dfc8b988c76575db53c,

title = "New therapeutics for chronic heart failure",

abstract = "Traditionally, clinicians have viewed heart failure either as a problem of excessive salt and water retention caused by abnormalities of renal blood flow, or as a hemodynamic problem associated with a reduced cardiac output and excessive peripheral vasoconstriction. Recently, clinicians have begun to adopt a neurohormonal model in which heart failure progresses because of the toxic effects of endogenous biological systems that become activated in heart failure. We review the rationale for existing heart failure therapies and discuss the reasoning behind the development of some emerging therapies.",

keywords = "Adrenergic nervous system, Cyokines, Left ventricular remodeling, Renin angiotensin system",

author = "Mann, {Douglas L.} and Anita Deswal and Biykem Bozkurt and Guillermo Torre-Amione",

year = "2002",

doi = "10.1146/annurev.med.53.082901.104004",

language = "English (US)",

volume = "53",

pages = "59--74",

journal = "Annual Review of Medicine",

issn = "0066-4219",

publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - New therapeutics for chronic heart failure

AU - Mann, Douglas L.

AU - Deswal, Anita

AU - Bozkurt, Biykem

AU - Torre-Amione, Guillermo

PY - 2002

Y1 - 2002

N2 - Traditionally, clinicians have viewed heart failure either as a problem of excessive salt and water retention caused by abnormalities of renal blood flow, or as a hemodynamic problem associated with a reduced cardiac output and excessive peripheral vasoconstriction. Recently, clinicians have begun to adopt a neurohormonal model in which heart failure progresses because of the toxic effects of endogenous biological systems that become activated in heart failure. We review the rationale for existing heart failure therapies and discuss the reasoning behind the development of some emerging therapies.

AB - Traditionally, clinicians have viewed heart failure either as a problem of excessive salt and water retention caused by abnormalities of renal blood flow, or as a hemodynamic problem associated with a reduced cardiac output and excessive peripheral vasoconstriction. Recently, clinicians have begun to adopt a neurohormonal model in which heart failure progresses because of the toxic effects of endogenous biological systems that become activated in heart failure. We review the rationale for existing heart failure therapies and discuss the reasoning behind the development of some emerging therapies.

KW - Adrenergic nervous system

KW - Cyokines

KW - Left ventricular remodeling

KW - Renin angiotensin system

UR - http://www.scopus.com/inward/record.url?scp=0036183553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036183553&partnerID=8YFLogxK

U2 - 10.1146/annurev.med.53.082901.104004

DO - 10.1146/annurev.med.53.082901.104004

M3 - Review article

C2 - 11818463

AN - SCOPUS:0036183553

SN - 0066-4219

VL - 53

SP - 59

EP - 74

JO - Annual Review of Medicine

JF - Annual Review of Medicine

ER -

New therapeutics for chronic heart failure

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this